drugset
drugset / Trial / NCT02106195

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

NCT02106195 ↗

Phase 2 Completed 8 enrolled Kadmon Corporation, LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.

Timeline

Start
2014-04
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Belumosudil Small molecule 200 mg Oral

Indications

psoriasis